These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 36439091)

  • 1. Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials.
    Wang J; Zhou H; Mu M; Zhao A; Cai Z; Li L; Wang M; Niu T
    Front Immunol; 2022; 13():1034253. PubMed ID: 36439091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.
    Wang Z; Zhou H; Xu J; Wang J; Niu T
    Front Immunol; 2022; 13():1070660. PubMed ID: 36685572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Matasar MJ; Capra M; Özcan M; Lv F; Li W; Yañez E; Sapunarova K; Lin T; Jin J; Jurczak W; Hamed A; Wang MC; Baker R; Bondarenko I; Zhang Q; Feng J; Geissler K; Lazaroiu M; Saydam G; Szomor Á; Bouabdallah K; Galiulin R; Uchida T; Soler LM; Cao A; Hiemeyer F; Mehra A; Childs BH; Shi Y; Zinzani PL
    Lancet Oncol; 2021 May; 22(5):678-689. PubMed ID: 33848462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of the PI3K inhibitor copanlisib in patients with relapsed or refractory indolent lymphoma: 2-year follow-up of the CHRONOS-1 study.
    Dreyling M; Santoro A; Mollica L; Leppä S; Follows G; Lenz G; Kim WS; Nagler A; Dimou M; Demeter J; Özcan M; Kosinova M; Bouabdallah K; Morschhauser F; Stevens DA; Trevarthen D; Munoz J; Rodrigues L; Hiemeyer F; Miriyala A; Garcia-Vargas J; Childs BH; Zinzani PL
    Am J Hematol; 2020 Apr; 95(4):362-371. PubMed ID: 31868245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility of Combining the Phosphatidylinositol 3-Kinase Inhibitor Copanlisib With Rituximab-Based Immunochemotherapy in Patients With Relapsed Indolent B-cell Lymphoma.
    Matasar MJ; Dreyling M; Leppä S; Santoro A; Pedersen M; Buvaylo V; Fletcher M; Childs BH; Zinzani PL
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e886-e894. PubMed ID: 34389273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pixantrone, etoposide, bendamustine, rituximab (P[R]EBEN) as an effective salvage regimen for relapsed/refractory aggressive non-Hodgkin lymphoma-Polish Lymphoma Research Group real-life analysis.
    Długosz-Danecka M; Hus I; Puła B; Jurczyszyn A; Chojnacki T; Blajer-Olszewska B; Drozd-Sokołowska J; Raźny M; Romejko-Jarosińska J; Taszner M; Jurczak W
    Pharmacol Rep; 2019 Jun; 71(3):473-477. PubMed ID: 31003160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
    Tobinai K; Igarashi T; Itoh K; Kurosawa M; Nagai H; Hiraoka A; Kinoshita T; Uike N; Ogura M; Nawano S; Mori S; Ohashi Y;
    Cancer Sci; 2011 Sep; 102(9):1698-705. PubMed ID: 21645173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
    Grunenberg A; Kaiser LM; Woelfle S; Schmelzle B; Viardot A; Möller P; Barth TFE; Muche R; Dreyhaupt J; Raderer M; Kiesewetter B; Buske C
    BMC Cancer; 2021 Jun; 21(1):749. PubMed ID: 34187401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
    Dreyling M; Morschhauser F; Bouabdallah K; Bron D; Cunningham D; Assouline SE; Verhoef G; Linton K; Thieblemont C; Vitolo U; Hiemeyer F; Giurescu M; Garcia-Vargas J; Gorbatchevsky I; Liu L; Koechert K; Peña C; Neves M; Childs BH; Zinzani PL
    Ann Oncol; 2017 Sep; 28(9):2169-2178. PubMed ID: 28633365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study.
    Shi YK; Hong XN; Yang JL; Xu W; Huang HQ; Xiao XB; Zhu J; Zhou DB; Han XH; Wu JQ; Zhang MZ; Jin J; Ke XY; Li W; Wu DP; Yang SM; Du X; Jia YQ; Liu AC; Liu DH; Shen ZX; Zhang LS; James L; Hellriegel E
    Chin Med J (Engl); 2021 May; 134(11):1299-1309. PubMed ID: 33967195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20
    Luo C; Wu G; Huang X; Ma Y; Zhang Y; Song Q; Xie M; Sun Y; Huang Y; Huang Z; Hou Y; Xu S; Chen J; Li X
    Sci Rep; 2021 Feb; 11(1):3255. PubMed ID: 33547368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and Efficacy Analysis of Selinexor-Based Treatment in Multiple Myeloma, a Meta-Analysis Based on Prospective Clinical Trials.
    Tao Y; Zhou H; Niu T
    Front Pharmacol; 2021; 12():758992. PubMed ID: 34925019
    [No Abstract]   [Full Text] [Related]  

  • 14. Safety and Efficacy of Anti-PD-1 Monoclonal Antibodies in Patients With Relapsed or Refractory Lymphoma: A Meta-Analysis of Prospective Clinic Trails.
    Zhou H; Fu X; Li Q; Niu T
    Front Pharmacol; 2019; 10():387. PubMed ID: 31118893
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies.
    Sun C; Chen H; Wang Y; Zheng C
    Hematology; 2023 Dec; 28(1):2181749. PubMed ID: 36892260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.
    Proudman D; Nellesen D; Gupta D; Adib D; Yang J; Mamlouk K
    Adv Ther; 2022 Apr; 39(4):1678-1696. PubMed ID: 35157216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and safety of subcutaneous rituximab in non-Hodgkin lymphoma: a systematic literature review and meta-analysis.
    Si T; Ma X; Zhu W; Zhou Y
    Hematology; 2023 Dec; 28(1):2284047. PubMed ID: 38010876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study.
    Fukuhara N; Maruyama D; Hatake K; Nagai H; Makita S; Kamezaki K; Uchida T; Kusumoto S; Kuroda J; Iriyama C; Yanada M; Tsukamoto N; Suehiro Y; Minami H; Garcia-Vargas J; Childs BH; Yasuda M; Masuda S; Tsujino T; Terao Y; Tobinai K
    Int J Hematol; 2023 Jan; 117(1):100-109. PubMed ID: 36175779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
    Jurczak W; Zinzani PL; Gaidano G; Goy A; Provencio M; Nagy Z; Robak T; Maddocks K; Buske C; Ambarkhane S; Winderlich M; Dirnberger-Hertweck M; Korolkiewicz R; Blum KA
    Ann Oncol; 2018 May; 29(5):1266-1272. PubMed ID: 29444231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bendamustine monotherapy for Chinese patient treatment with relapsed or refractory B cell non-Hodgkin lymphoma: a phase Ⅱ, prospective, multicenter, single-arm study].
    Gao Y; Yang Y; Cen H; Liu H; Fu JX; Wang SQ; Feng R; Yu D; Zhang XY; Chen ZW; Li YF; Huang HQ
    Zhonghua Xue Ye Xue Za Zhi; 2022 Nov; 43(11):934-939. PubMed ID: 36709185
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.